GlassScriptPhysician profile
Matthew Allen Bye
NPI 1588303754
$2,857.02
in general payments reported to CMS, 2019-2025
10 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 82% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $12.75 · 2024: $821 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.08 |
| Education | $119.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $727.62 | 2025 | Accolade Sr, Ams 700 |
| Davol INC. | $646.35 | 2024-2025 | Phasix Mesh |
| W. L. Gore & Associates, INC. | $452.76 | 2024-2025 | Gore Viabahn Vbx Balloon Expandable Endo, Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore-Tex Vascular Graft |
| Biocomposites INC | $233.09 | 2025 | Stimulan |
| Penumbra, INC. | $206.54 | 2024-2025 | Penumbra System |
| Medtronic, INC. | $201.66 | 2023-2025 | Endurant Iis, Signia |
| Lemaitre Vascular, INC. | $144.75 | 2024 | Restoreflow, Artegraft Vascular Graft |
| Becton, Dickinson and Company | $115.21 | 2024 | Phasix Mesh |
| Stryker Corporation | $111.23 | 2025 | Flowtriever |
| Ethicon US, LLC | $17.81 | 2024 | Certus 140 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.